Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019...
NANOBIOTIX : Résultats positifs de la Phase II/III dans les Sarcomes des Tissus Mous avec NBTXR3 présentés à l’ESMO
October 19, 2018 12:05 ET
|
NANOBIOTIX
NANOBIOTIX : RESULTATS POSITIFS DE LA PHASE II/III DANS LES SARCOMES DES TISSUS MOUS AVEC NBTXR3 PRESENTES A L’ESMO Dr. Sylvie Bonvalot, Chef du Service Sarcomes et Tumeurs Complexes de...
NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
October 19, 2018 12:05 ET
|
NANOBIOTIX
NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris,...
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
June 11, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
June 02, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
May 24, 2018 08:00 ET
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
September 08, 2017 04:00 ET
|
Immune Design Corp
Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy...
AntiCancer PDOX Reaches Series A Financing Target, Appoints Board
June 01, 2017 16:24 ET
|
AntiCancer PDOX, Inc.
CHICAGO, June 01, 2017 (GLOBE NEWSWIRE) -- ASCO 2017 -- AntiCancer PDOX, Inc. announced today that it has reached its original Series A financing target and appointed its Board of...